US Patent 8,754,070: Scope, Claims, Expiration, Orange Book Status, and AndroGel 1.62% Patent Landscape

US Patent 8,754,070 protects a narrowly defined testosterone gel composition associated with AndroGel 1.62%. Its core limitation is a formulation containing exactly 1.62% testosterone, 1.0% isopropyl myristate, 68.1% absolute ethanol, 1.0% of a neutralized anionic polymer, and water. The patent does not broadly cover all testosterone gels.

The most commercially important claim is claim 6, which requires a carbomer neutralized with sodium hydroxide. Claim 8 links the composition to a 40.5-mg testosterone dose, corresponding to 2.5 grams of a 1.62% testosterone gel. The patent is a small-molecule formulation patent, not a biologic patent, so biosimilar procedures do not apply.

What drug does US Patent 8,754,070 protect?

US 8,754,070 protects a specific hydroalcoholic testosterone gel formulation. The formulation is associated with AbbVie’s AndroGel 1.62%, an FDA-approved testosterone replacement product for men with testosterone deficiency associated with hypogonadism.[1]

Product attribute	Protected formulation
Active ingredient	Testosterone
Testosterone concentration	1.62% w/w
Isopropyl myristate	1.0% w/w
Absolute ethanol	68.1% w/w
Gelling agent	1.0% w/w neutralized anionic polymer
Preferred polymer	Carbomer
Preferred neutralizer	Sodium hydroxide
Dose identified in claim 8	40.5 mg testosterone
Corresponding gel quantity	2.5 g
Dosage form	Topical gel
Therapeutic use	Treatment of hypogonadism in human males

A 2.5-gram application contains 40.5 mg of testosterone because:

2.5 g × 1.62% = 0.0405 g = 40.5 mg

The claim does not mean that 40.5 mg is necessarily the amount systemically absorbed. It is the nominal testosterone content in the administered gel dose.

When was US Patent 8,754,070 issued and when does it expire?

US Patent 8,754,070 was granted on June 17, 2014. Its nominal patent-term endpoint is reported as September 27, 2027, subject to any applicable patent-term adjustment, patent-term extension, terminal disclaimer, or other USPTO record affecting the specific patent.[2]

Milestone	Date or status
Patent number	US 8,754,070 B2
Grant date	June 17, 2014
Patent type	Formulation and method-of-treatment claims
Reported nominal expiration	September 27, 2027
Regulatory product association	AndroGel 1.62%, NDA 022309
Small-molecule or biologic	Small molecule
Biosimilar pathway	Not applicable

The nominal expiration date is distinct from FDA marketing exclusivity. FDA exclusivity may expire before the patent, while an enforceable patent can continue to restrict commercial launch after regulatory exclusivity ends.

What are the independent claims of US 8,754,070?

Claim 1 is the principal composition claim. It requires all of the following:

1.62% w/w testosterone;
1.0% w/w isopropyl myristate;
68.1% w/w absolute ethanol;
1.0% w/w of an anionic polymer;
neutralization of that polymer with enough neutralizer to form a gel; and
water.

The claim uses “consisting of,” which is materially narrower than “comprising.” A composition that contains an additional ingredient may fall outside the literal scope of claim 1 if the additional ingredient is viewed as an unlisted component rather than an impurity, processing aid, or incidental material.

The claim also requires the stated concentrations. It does not provide broad numerical ranges. That creates a potentially significant design-around route, although a court could consider equivalents depending on the prosecution history and the technical effect of the altered concentration.

How do claims 2 through 7 narrow the patent scope?

Claims 2 through 7 create a nested claim structure.

Claim	Limitation	Practical effect
1	Core gel composition	Broadest composition claim in the issued patent
2	Anionic polymer is polyacrylic acid	Narrows polymer class
3	Anionic polymer is carbomer	Narrows to a commonly used polyacrylic-acid polymer
4	Lists permitted neutralizers	Defines a Markush group of neutralizers
5	Neutralizer is sodium hydroxide	Narrows to sodium hydroxide
6	Carbomer neutralized with sodium hydroxide	Specific formulation combination
7	Carbomer plus sufficient sodium hydroxide to form a gel	Similar commercial formulation limitation
8	40.5-mg testosterone dose for hypogonadism	Adds dose and treatment-use limitations

Claim 2: Polyacrylic acid

Claim 2 covers a polyacrylic-acid anionic polymer. A carbomer is generally a cross-linked polyacrylic-acid polymer, which is why claim 3 narrows further to carbomer.

Claim 3: Carbomer

Claim 3 is commercially important because carbomer is the polymer identified in the most specific claims. A competing product using a different gelling system, such as a cellulosic polymer, poloxamer, or nonionic thickener, would have a stronger noninfringement position under claims 3, 6, and 7.

Claim 4: Neutralizer Markush group

Claim 4 lists:

sodium hydroxide;
ammonium hydroxide;
potassium hydroxide;
arginine;
aminomethyl propanol;
tetrahydroxypropyl ethylenediamine;
triethanolamine;
tromethamine;
PEG-15 cocamine;
diisopropanolamine;
triisopropanolamine; and
combinations of those materials.

The claim is broader than claim 5 because it covers multiple neutralizers. A product using a neutralizer outside this list could avoid literal infringement of claim 4, but it would still need to avoid claim 1 and any other relevant patent claims.

Claims 6 and 7: Commercially concentrated protection

Claims 6 and 7 concentrate protection around a practical formulation:

1.62% testosterone;
1.0% isopropyl myristate;
68.1% ethanol;
1.0% carbomer;
sodium hydroxide; and
water.

Claim 6 describes the carbomer as neutralized with sodium hydroxide. Claim 7 separately recites an amount of sodium hydroxide sufficient to form a gel. These claims provide fallback positions if broader claims are challenged.

What does “consisting of” mean for infringement analysis?

“Consisting of” generally closes the composition to additional components that materially change the claimed formulation. The analysis is fact-specific, but the closed transition creates more limited literal scope than “comprising.”

A competing product could reduce risk by changing one or more required limitations, such as:

using 1.60% or 1.70% testosterone rather than 1.62%;
changing ethanol concentration;
omitting isopropyl myristate;
using a different emollient or penetration enhancer;
using less or more than 1.0% carbomer;
using a non-carbomer gelling agent;
using a neutralizer outside the listed group;
changing the dose or administration instructions.

These changes do not automatically eliminate infringement risk. The doctrine of equivalents can reach insubstantial substitutions, particularly where the substitute performs substantially the same function in substantially the same way to achieve substantially the same result. The prosecution history is therefore important in evaluating any proposed formulation design-around.

What is the Orange Book status of US 8,754,070?

US 8,754,070 has been associated with the Orange Book-listed AndroGel 1.62% product under NDA 022309.[3] Orange Book listing gives the patent regulatory significance because an ANDA applicant referencing the drug may need to make a patent certification.

Regulatory issue	Assessment
Reference product	AndroGel 1.62%
NDA	022309
FDA pathway for a generic	ANDA
Patent certification	Paragraph IV may be used for an unexpired listed patent
Biosimilar application	Not applicable
Regulatory exclusivity	Separate from patent expiration
Patent-listing effect	May trigger a 30-month stay if the NDA holder timely files suit

The Orange Book does not determine whether the patent is valid or infringed. It identifies patents submitted by the NDA holder as relevant to the listed drug. Patent litigation, claim construction, validity rulings, settlements, and launch rights must be analyzed separately.

What Paragraph IV risks apply to testosterone gel 1.62%?

A generic applicant can challenge US 8,754,070 through a Paragraph IV certification. The applicant would state that the patent is invalid, unenforceable, or not infringed. The reference sponsor may then file an infringement action within the statutory period, potentially triggering a 30-month stay of FDA approval under the Hatch-Waxman framework.[4]

The principal Paragraph IV arguments would likely include:

Lack of literal infringement

A generic applicant could certify that its product does not contain the exact combination or concentrations required by the claims. The strongest noninfringement arguments would involve:

a different testosterone concentration;
a different ethanol concentration;
a different amount or identity of the gelling agent;
no isopropyl myristate; or
a different neutralizer.

Obviousness

The challenger could argue that the claimed formulation would have been obvious based on earlier testosterone gels, hydroalcoholic vehicles, carbomer gel systems, penetration enhancers, and known testosterone replacement products. The patent holder would likely rely on formulation performance, dosing consistency, absorption, skin tolerability, stability, or other unexpected properties.

Anticipation

Anticipation would require a single prior-art reference disclosing every limitation, including the narrow concentration profile. Exact numerical limitations can make anticipation difficult unless an earlier product specification or formulation example discloses the same composition.

Written description and enablement

These arguments are less likely to focus on the basic concept of a testosterone gel and more likely on whether the disclosure supports the exact claimed concentrations, neutralizer alternatives, and full scope of the Markush group.

Which companies have challenged testosterone gel 1.62% patents?

The major competitive challenge has come from ANDA manufacturers seeking approval for generic testosterone gel 1.62%. Teva and other generic manufacturers have been involved in the broader AndroGel 1.62% patent challenge and commercial-entry landscape.[5]

Generic approval and patent clearance are separate events. FDA approval means the product met the agency’s requirements for quality, safety, bioequivalence, and labeling. It does not necessarily establish that all Orange Book patents are invalid, not infringed, or licensed.

The commercial risk depends on the applicant’s certification, the patents challenged, the litigation outcome, and any settlement terms governing launch.

What litigation and settlement issues affect US 8,754,070?

The relevant litigation pattern is Hatch-Waxman litigation involving ANDA applicants for testosterone gel 1.62%. The key questions are:

Was US 8,754,070 included in the asserted patent set?
Did the applicant make a Paragraph IV certification?
Was the patent challenged on infringement, validity, or enforceability grounds?
Did the parties settle?
Did the settlement permit an agreed launch date before patent expiration?
Did the settlement include a license, authorized generic arrangement, or supply agreement?

Public litigation involving AndroGel patents has included disputes between AbbVie-related entities and generic applicants. The patent landscape includes multiple related patents, so a favorable result on one patent does not necessarily clear the full estate.

A generic applicant can win on noninfringement of US 8,754,070 and still face other Orange Book patents covering the same reference product, method of use, formulation, or commercial presentation.

How strong is the patent estate for AndroGel 1.62%?

The estate is strongest against products that copy the commercial formulation closely. Its strength is lower against products that use a materially different vehicle or gel system.

Risk factor	Assessment
Exact composition copying	High infringement exposure
Use of carbomer and sodium hydroxide	High exposure under claims 6 and 7
Use of listed neutralizer with claimed composition	Meaningful exposure under claim 4
Different gelling agent	Reduces risk under claims 3, 6, and 7
Different ethanol level	Potentially strong noninfringement position
Different testosterone concentration	Potentially strong noninfringement position
Different penetration enhancer	Reduces risk if isopropyl myristate is absent
Use of same 40.5-mg dose	May increase method-of-use exposure
Challenge to patent validity	Depends on prior art and prosecution history
Overall estate risk	Must be assessed against all listed patents, not this patent alone

The patent is technically narrow but commercially relevant because generic developers often seek to approximate the reference product for formulation, manufacturing, labeling, and bioequivalence reasons. The closer the proposed product is to the listed formulation, the more important this patent becomes.

What manufacturing and formulation barriers does the patent create?

The patent can create a formulation barrier even where the individual ingredients are old. The claimed combination fixes several parameters simultaneously:

testosterone loading;
ethanol content;
isopropyl myristate content;
carbomer or other anionic polymer content;
neutralization chemistry; and
water balance.

A manufacturer designing around the patent must preserve acceptable viscosity, testosterone solubility, dermal delivery, drying time, stability, packaging compatibility, and patient usability. Changing the formulation can create new development and regulatory burdens even if it reduces patent risk.

Manufacturing records also matter. A product that nominally uses a different composition may still require analysis of batch specifications, release testing, process tolerances, and actual composition. Infringement may turn on the commercial product as made and sold, not merely on a public formulation description.

How does US 8,754,070 compare with other testosterone products?

Product	Delivery system	Typical formulation distinction	Patent relevance
AndroGel 1.62%	Topical gel	1.62% testosterone hydroalcoholic gel	Directly relevant
AndroGel 1%	Topical gel	Lower testosterone concentration	Different product and patent profile
Testim	Topical gel	Different gel formulation and excipient profile	Competing topical estate
Fortesta	Topical gel	Higher concentration and different dosing system	Separate formulation and use claims
Axiron	Topical solution	Underarm topical solution	Different delivery system
Natesto	Nasal gel	Intranasal administration	Method and device patents differ
Jatenzo	Oral capsule	Oral testosterone undecanoate	No direct formulation overlap

US 8,754,070 does not cover testosterone as an active ingredient generally, all hypogonadism treatments, or every topical testosterone formulation.

What generic launch scenarios exist?

Launch after patent expiration

A generic can launch after the relevant enforceable patents expire, assuming FDA approval and commercial readiness. On the reported schedule, the key date for US 8,754,070 is September 27, 2027.

At-risk launch

A generic applicant may launch before expiration after obtaining approval and prevailing in litigation, obtaining a covenant not to sue, or relying on a legal position that the relevant patent does not block launch. An at-risk launch exposes the applicant to damages and injunctive relief if the patent is later upheld and found infringed.

Licensed or settlement launch

A settlement may establish a permitted entry date before patent expiration. The economics depend on the negotiated date, whether the license is exclusive or nonexclusive, and whether the brand company supplies an authorized generic.

Design-around launch

A company may use a different concentration, vehicle, gelling agent, neutralizer, or penetration enhancer. This route can reduce infringement risk but may require additional formulation and bioequivalence work.

Does US 8,754,070 create biosimilar risk?

No. Testosterone is a chemically synthesized small molecule. A competing testosterone gel would proceed through the generic-drug framework, usually an ANDA, rather than the biosimilar pathway under the Public Health Service Act.

The relevant competitive issues are:

pharmaceutical equivalence;
bioequivalence;
formulation similarity;
labeling;
Orange Book patents;
Paragraph IV certification;
Hatch-Waxman litigation; and
state substitution and pharmacy-channel access.

Key Takeaways

US 8,754,070 is a narrow formulation patent associated with AndroGel 1.62%.
Claim 1 requires exact stated concentrations of testosterone, isopropyl myristate, ethanol, and an anionic polymer, plus water.
Claims 3, 6, and 7 concentrate commercial protection around carbomer and sodium hydroxide.
Claim 8 covers a 40.5-mg testosterone dose, corresponding to 2.5 grams of 1.62% gel.
The “consisting of” transition limits literal scope and creates potential design-around opportunities.
The reported nominal expiration date is September 27, 2027.
The patent is relevant to ANDA applicants, not biosimilar applicants.
A generic applicant can challenge the patent through Paragraph IV certification.
FDA approval does not establish patent clearance.
The commercial risk must be assessed against the full AndroGel 1.62% Orange Book estate, not US 8,754,070 alone.
Products that copy the carbomer, sodium hydroxide, ethanol, isopropyl myristate, and 1.62% testosterone profile face the highest formulation-infringement risk.

FAQs

Is US 8,754,070 a patent on AndroGel itself?

It is a patent on a specific testosterone gel composition associated with AndroGel 1.62%. It is not a patent covering every testosterone gel or every use of testosterone.

Can a generic use carbomer and avoid US 8,754,070?

Possibly, but not automatically. The generic would need to avoid the full combination of claimed concentrations, ingredients, neutralization conditions, and any relevant method-of-use limitations.

Does changing 1.62% testosterone to 1.60% avoid infringement?

It may support a literal noninfringement position because the claim recites 1.62% rather than a range. The doctrine of equivalents and prosecution history would remain relevant.

Is the 40.5-mg dose itself patented?

Claim 8 includes the 40.5-mg dose as part of a claim to the claimed gel composition used to treat hypogonadism. The dose limitation should be analyzed together with the formulation limitations.

Can an FDA-approved generic launch before September 2027?

Yes, if the applicant clears the applicable patents through litigation, settlement, license, patent expiration, or a successful design-around. FDA approval alone does not provide a complete patent clearance.

References

U.S. Food and Drug Administration. (2011). AndroGel 1.62% testosterone gel prescribing information. FDA.
United States Patent and Trademark Office. (2014). U.S. Patent No. 8,754,070, Testosterone gel compositions. U.S. Department of Commerce.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j).
U.S. District Court for the District of Delaware. (n.d.). AbbVie Inc. and related entities v. generic applicants concerning AndroGel 1.62% ANDA submissions. PACER and publicly reported docket materials.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Besins Hlthcare	ANDROGEL	testosterone	GEL, METERED;TRANSDERMAL	022309-001	Apr 29, 2011	AB	RX	Yes	Yes	8,754,070	⤷ Start Trial	Y				⤷ Start Trial
Besins Hlthcare	ANDROGEL	testosterone	GEL;TRANSDERMAL	022309-002	Sep 7, 2012	AB2	RX	Yes	No	8,754,070	⤷ Start Trial	Y				⤷ Start Trial
Besins Hlthcare	ANDROGEL	testosterone	GEL;TRANSDERMAL	022309-003	Sep 7, 2012	AB2	RX	Yes	No	8,754,070	⤷ Start Trial	Y				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2006299833	⤷ Start Trial
Brazil	PI0617294	⤷ Start Trial
Canada	2624788	⤷ Start Trial
China	101287470	⤷ Start Trial
Cyprus	1113737	⤷ Start Trial
Cyprus	1120904	⤷ Start Trial
Denmark	1937276	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 8,754,070